Infant Bacterial Therapeutics gets Orphan Drug Designation in Europe

25-Feb-2015 - Sweden

Infant Bacterial Therapeutics (IBT), subsidiary of BioGaia, is in the early stages of developing a drug to prevent necrotizing enterocolitis (NEC) which is a rare and fatal disease that affects premature infants. IBT has now obtained the Orphan Drug Designation for the prevention of NEC in Europe, which complements the corresponding designation in the US from FDA, granted in August 2013.

“We are pleased that the European Commission have granted the Orphan Drug Designation. We are confident that our subsidiary IBT can significantly contribute in the care of premature infants in the future”, says Peter Rothschild, CEO, BioGaia.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances